Metastasis to the brain is a frequent complication of systemic cancers occurring in 10 to 40% of all patients, and is the most common intracranial tumor (approximately 40%) in adults which has an incidence 10 times higher than that of primary malignant brain tumors.
Diagnosis
The signs and symptoms of brain metastasis are related to the involved brain area. The most common symptoms are gradual onset of headache, focal weakness, and mental changes.
Generalized or focal seizures may also occur in 20% of patients.
Hemorrhage into the tumor can result in an acute stroke-like presentation. Hemorrhage is present in 3~14% of metastases and is commonly seen in metastases from melanoma, choriocarcinoma, renal, thyroid, lung, breast, and germ cell tumors. The median latent interval between the initial diagnosis of a primary tumor and diagnosis of brain metastases is 6~9months for lung cancer and 2~3years for melanoma, breast, and colon cancer.
CT or MRI can establish the diagnosis of brain metastases, but contrast-enhanced MRI is more sensitive than enhanced CT for determining the presence, location, and number of brain 
Prognostic factors
The overall prognosis of brain metastasis has improved over the past two decades with the use of combined therapy.
Regardless of the histological features of the primary tumor, patients who received only supportive therapy had median survival of 1~2months. Radiotherapy improved survival by 3~4
months. Among patients with a single metastasis, those who underwent surgical resection with the addition of radiation therapy had a 7-to 9-month increase in median survival. 
Definitive treatment
Definitive therapy is directed against the tumor itself and designed to eradicate or at least diminish the malignancy.
Surgery, radiosurgery and conventional radiotherapy are the most commonly used treatment modalities. 
Conclusion
Advances in systemic cancer management have resulted in a significant increase of patients with brain metastases. Metastatic brain tumors limit the patient's survival and worsen the quality of life through an increase risk of developing neurological and cognitive deficits. Although the prognosis is still poor, aggressive local treatment can benefit to patients with brain metastases.
